weeks to 54 (maa u) * ISI nwnths. Rmpective evaluation of serial pulmonary function tests in 61 patients demonstrated both a significant decrease from baseline in three of stx vatibter in patRots with toxicity at the tilne of ding"& and P siguttIca"t difference compared with the sane variahtrs in pattents without toxicity. Tk mart signifrcat of thesa was the dbTwt"g capacity for carban m"""xide &CO). An individual decrease in D,.CO ~15% gave a" Amiadarone was first introduced in Europe in 1967 as an antianginal agent and subsequently found to have potent antiarrhythmic pmpenies. Initial reports emphasized its remarkable clinicai etfcacy in a variety of cardiac arrhythmias. Withfurtherexperience, however, avariety ofadverse etkcts have become well recognized. of which pulmonary fibrosis remains the most serious because of its potentially life-threatening nature.
Since a possible association between amiodnrone and pulmonary fibrosis was first described in 1980 (I). the reported incidence of amiodarone-induced pneumonitis has been highly variable (between 0.5 I21 and 17.6% 131). a disparity that may be due in part to the lack of established diagnostic criteria. Some investigators (4.5) have attempted to identify potential risk factors for the development of pulmonary toxicity, including preexisting lung disease and pulmonary function abnormalities. but their conclusions have not been supported by others (61.
Thtc study was conducted I) to define the incidence of pulmonary toxicity in patients treated with amiodorone with use of specified clinical diagnostic criteria. and 2) to determine prospectively the role of pulmonary function testing in the prediction of risk and diagnosis of pulmonary toxicity. Other powble risk factors. including dose, were analyzed in a" attempt to identify any patients who might be at special risk for this complication.
Melhods
Palient mwo (Table II. The total patient group consisted of all 89 c&se&tive referred pat&s who were started on oral amiodarone therapy between March 1981 and June 1985 and followed up through July 1986. Prospective follow-up on all 89 patznts was complete. The actuarial incidence of pelmonory roxicify and the derermir~ntion of clinical predicms of this complication were drmvnfiwi Ibis Ioral group.
The probpective study of pulmonary function. was performed i" a cohon drawn from the 89 patients. Fourteen patients did not undergo baseline pulmonary function tests because o: frequency of life-threatening arrhythmia 14 patients) or severe congestive heart failure (IO patients); 4 of these 14 patients later developed pulmonary toxicity. In the remainmy. 75 patients, analysis of baseline pulmonary function was performed. Eight addilional patients did not have follow-up studies because of early death (three patientsj. severe respimtory distress secondary to amiodarone pulmonary mvicity (three patients) or transfer of clinical care to anorher institution (two patients). Sixty-seven patients, therefore. completed both baseline and follow-up pulmonary function tests; their clinical characteristics are shown in Table I alonp with those of the tolal patient group, Amiudwunc dosing. The srandard oral loadiug dose was 1.4tio mgtday and was used in 91% oipatienls. However, this dose ranged between 800 and I.603 mglday with u mean loading dose of 1.380 q/day for the enlirc group. Duration of loading was I to 5 hnean 3) weeks. Both the dose and duration of loading were influenced hy the severity of the presenting arrhythmia, the development ofadverse effects or the pattent's clinical response. The dose was then decreased tu 400 to 6M) midav until the end of the 2nd month of ,rcatmenr and folio&d by a mainlenance dose of 200 to 600 r&day 0nean 3X mg). Although chosen arhhrarily. lhis dose was also influenced by the presence of side effeclr or arrhythmia recurrence. Sixteen patients required concomitant antiarrhythmic therapy for arrhythmia control during amiodamne loading: lidocaine in five patients, procainamide in five, quinidme in three and propranolol in three. Only one padem war discharged on combination therapy (amroderunc and procainamide) with amiodarone being wntinued alone afler2 months. Three others were subsequently started on a betweceptor blocking drug in combination with a&da-row however, only one patient has required chronic low dose lherapy with atenolol. During the course of amiodarone therapy. no patient was taking corticosteroids or any drug known 1o crtusc pulmonary fibrosis. In patients with suspected pulmonary toxicity, the diagnostic investigulioo included hospitalization, chest roentgenogram, pulmonary function testing when possible, gallium67 lung scanning, branchoscopy and transbmhchial biopry. Gallium-67 lung scintigmbhy was perfornxd 48 h after the intravenous injection of 5 mCi of gullium-67 citrate. Scanning was performed with an Atiger scintillation camera and the uptake in lung parenchyma on poslerior views scored from 0 to 41 as previously described (9). All gallium-67 lung scans were interpreted and reviewed by an independent expert without knowledge of the @ant's clinical history. Amiodamne was discontinued in all patients with suspected toxicity and corticosteroid therapy was instituted in Ihe majority. In an attempt to control recurrence of arrhythmia, some patients were rechallenged with amiodarone either with or without concomitant steroid therapy. D&u&ii criteria. Our cntena tor the dlagnasis of pulmonary toxicity required Iwo essential fealures: 11 dyspnea and cough. and 2) the prcscnce of new or progressive pulmonary infiltrates on chest roentgenogram. I" addition. the presence of any two of the fellowmg four supp"rti"a criteria were required: 1) n" response to specific thenpy fur other possible causes such "s congestive heart failure or pneumonia: 2) recovery on discontinuation of amiodarone: 3)fccurrenceof symptomson rechallenge;and4)compatible puhnonafy histolugic tidings.
Slstisticsl analysis. Data were analyzed using the CLINFO datu analysis system. Kaplan-Meier methnds were used to display the actuarial incidence of pulmonary toxrcity. The Student's r test for paired and unpaired data and chisquare analysis with Yates' correction for continuity were used where app~rkttc.
The Wilcoxon non-wired rank sum test was employed where data were not nortnally distrtbuted.
Values arc reponed as mea" ? I SD. A probability (p value) SO.05 was defined es significant. Diagnusfic erilerla. During a follow-up period of 2 weeks lo 54 (mean 20 * IS) months, pulmonary toxicity was diagnosed in I5 of 89 patients, a" overall incidence mte uf 17%. The pmbability of developing pulmonary toxicity war It% after6 months, 15.5% after I year and 1% efter 2 years (Fin. I). The diagnostic criteria fulfilled in these I5 patients were as follous. All patients presented vjith dyrpnea. cough and new pulmonary infiltrates on chest rocnrgenogram. Before the diagnosis was suspected, seven patients received therapy for congestive heart failure or pneumonia and failed to respond. Ammdarene war discontinued in an 15 patients. Thirteeu patients recovered. 10 of whom received prednis""e. Two patients died. one "t whom bad received prednisane late in the course of illness. Six patients were suhsequently rechallenged with a lower dose of amiodarone. Four of the six developed recwrence of symptoms despite con- Thus, ii: patients with toxicity, the FVC, PI& and D,CO demonstrated not only a clinically meaningful and signiii&t decrease from baseline but also a significant difference compared with values in patients who never developed pulmonary toxicity. The decrease in PO, does not reflect the marked hypoxia seen in three patients who were too r,;k to perform pulmonary function tests at the time of presentation with symptoms. The .createst decrease in any index in patient; v&h po!mona~ toxicity was the decrea& in &CO (34.5 + 13X%), which was highly statistically different from an increase of 8.6 + 25.7% in patients without toxicity. 7. Among I2 other patients taking &niodarone who had dyspnea and cough due to causes other than amiodarone (heart failure in 9, pneumonia in 2 and recurrent pulmonary embali in I). the gallium-67 scan was negative in each (p < 0.031). Thus, the sensitivity of a positive gallium-67 lung Gallium-67 lung scan. A gallium-67 scan of the lungs was positive in IO of II patients, scores ranging from It to 4+ scan for the diagnosis of pulmonary toxicity was 91%. the (mean Ztl: the udake was focal in 3 oatients and diffuse in specificity of the test was 100% and the predictive value afa positive test in this group of patients receiving andodamne was Ml%.
Potential risk factors. One objective of this siudy was to identify any potential risk factors for the development of pulmonary tcxicity. The distribution of pulmonary toxicity in the I5 padera WE first examined accordine to duration of therapy. Eleven patients 03%) developed sy&ptoms within the first 7 months of treatment. In three ofthese patients, the first signs of toxicity appeared during the loading period at 13, I5 and 30 davs of treatmeot with 1.400 me/dav of ",--amiodarone. The &nical status of these patients deteriorated repidly, and they required intubation and mechanical ventilation within 3 to IO days after the onset of symptoms. Seven of the remaining eight patients developing early toxicity were receiving a maintenance dose of 600 &day and one was receiving P. dose of 400 mglday. Of the four patients who developed pulmonary toxicity later in the course of treatment, all hut one, receiving 2OG &day. were receiving a maintenance dose of 400 mglday at the time of presentation with symptoms. However, two of these four Who developed toxicity at I5 and 28 months, respectively) had been receiving a higher maintenance dose ot 400 mg and 600 @day, respectively, foi recwreot ventricular tachycardia and had received an arbitrary dose reduction only shortly before the onset of symptoms. former grow was receiving a mean maintenance dose of 527 This 11n~sual1y high incidence ofpulmonary toxicity during the enrly wonrhs of treatment wilh omiodorone prompted us to look more closely at the relation between dose and duration of therapy. Analysis of the maintenance dose at 3 and 6 months of treatment demonstrated that, at both time intervals, the patients with subseaoent toxicitv were taking a significantI; higher daily dose ban were th; patients who never developed toxicity. At 3 months, the Olher potential risk factors did not differentiate the pnlients who become toxicfrom those wirhour roxicify: these included age, left ventricular ejection fraction, history of congestive heart fai!ure or cigarette smoking, total loading dose in grams. loading dose in mgikg per day or duration of loading (Table 2 ). In particular, a history of pulmonary discas; or an abnormal chest roentgeoogram was no more prevalent in patiems with than in those without pulmonary toxici*y.
Baseline pslmonary funcfiz~ also did not differ signi/icantly befween these IWO groups in the 75 patients who underwent pulmonary function tests before amiodaronc therapy (Fig. 3) . On the basis of these studies. preexisting obstructive lung disease was present in 31 (48%) of 64 patients without pulmonary toxicity aad in 5 (46%) of II patients with t&city (p = NSL 111; incidence ofrestrictive lung disease ~85 also similar in the two groups (16% versus 20%. respectively). Baseline values for d&&g capacity for carbon monoxide CD,CO) were also comparable: a wan of 66 * 21% of the predicted value in the former patients and 68 2 16% of the predicted value in the latter (p = NS). Althoueh a total of 25 (34%) of 73 baiients had an abnomtal baseline D,CO, only i of ihese patients eventually devclaped pulmonary toxicity. Eleven (15%) of 73 patients had both an abttormal baseline D,CO and chest mentgenogmm end none of these patients developed pulmonary mxicity. Thus, abnomtrd baseline wlmonary function includine en ahnomel DLCO either &me or k combination witi an initial abnormal chest rcatgenwem did nat predict the development of pulmonary toxicity.
D+mticvpltleofdeeruueittD,C0betweeohvotertr (Tshie 3). Becattse a decrease in diffusing capacity for carbon monoxide (D,CO) was the most striking laboratory lindiog at the time of diagnosis, we analyzed the diagnostx value of a decrease in D,CO between any two successive tests. Two hundred eighty-six pulmonary function tests, Table 3 . Diagnostic Valw cd Serbal Testing of DbTuring Capacity d the Lung for Carbon Monoxide &CO, -inciuding 67 baseline tests and 219 follow-up ~~1s. were analyzed in the 67 patients. !lecreases of IS, 20. end 30% were tested as a merkeroftonicity. Of the I8 follow-up tests perfumed in the eight patients who later developed pulmonary toxicity. none demonstrated a significant decrease in D,CO unti! the time of diagnosis. That is, IO of these follow-up tests were petfomted et a time when pulmonary symptoms were absent and were considered to be non. diagnostic as were the 201 follow-up tests performed in the 59 patwts without pulmonary toxicity. Maximal sensitivity of IOO% WBE obtained with a alS% decreaw and maximal specificity of 98% wi!h a ~30% decrease. As expected, intermediate sensitivity and specificity were associated with a 220% decrease. The posi:ive diagwx:if value of a decrease in D,CO of 215. 20 or 3G% WE. 25, 37 and Ml%, res~ectwelv. On the other hand. rhe probability that a patient with <IS% decrease ie D,CO had puhn&y toxicity was extremely low (negative diagnortic value lOG?@. Compared with the D,_CO, none of the other pulmonary function tests yielded a similar sensitivity, specificity or diagnostic accuracy for the diagnosis of pulmonary toxicity.
Diagttas~ of ptdmoeary toxicity. Pulmonary fibrosis is now a well recognized complication of amicdarone therapy. Its reported incidence. although variable. has remained getter&y low. The diagnasis of &niodarone-induced pulmw nary toxicity is difficult, with findings often indistinguishable from those of catgestive heart f&re or pneunwnia. Although it is generally accepted that this syndrome is charecterized by dyspnea, cough. pulmonary infdtretes, restrictive changes on pstmonaty function testing and compatible histologic findings, the diagnosis has oflen been made retrospectively and by exclusion of alternative causes. Without a high index d suspicion for its recognition and specified criteria on which to bese lhc diagnosis, symptotns or deeth in individual patients may be asprihed 10 pro_"sive heart failure or respiratory infection and the real incidence underestimated. On the other hand, a diagnosis of pulmonary toxicity based an less than stringent criteria could lead 10 the premature discontinuation of amiodarotte and loss of potential lone-term benefit in the group of patients who most likely need i; the most. For ex&pl~. ii one other prospective studv in which diaetmstic criteria were defined. Kttdenchuk et al. (5) diagnosed pulmonary toxicity by new or worsening interstitial infiltrateson chest raentgenogramassociated with worsening measurements of total lung or diffusing capacity.
with or without ~ulntatary symptoms; they recommended dose reduction or discontinuation of amioderone even in asymptomatic patients meeting these criteria. Such asymptomatic patients were also included in two smeller reported series (3.12). raising the interesting possibdity that a deiectable subclinical phase of the illness may occur. In the present study WC regarded the presence of pulmonary symp twos as one of two essential criteria in determining the diagnosis. Future agreement among clinicians regarding diagnostic criteria would facilitate the early recognition and accurate diagnosis of this complication and thus help establish the real incidence.
The rule of pulmonary fuaellon testing in the diagnosis 01 pulmonar, toxicity. This role has not been examined in previous reports. Of three prospective studieb reporting the Lsults of berial pulmooaj f&ion tests (S,6.l3), none examined the potential diagnostic value of such studies. Although Adams et al. (13) noted a small overall decrease in D,CO in 34 patienls after 3 months of amiodarone therqj. both Kudenchuk (5) and Rakita (6) and coworkers found no significant change in mean pulmonary function test measurements before and after amiodarone therapy in their patient population as a whole. A similar analysis of our data supports the latter findings: mean values before and after amiodamnc therapy for FEV,. FVC. FEV,,FVC. TLC. 00, and D,CO were.iochaoged: However, ai analysis of-th; same variables first compared before and after therapy in patients wilh pulmonary loxicily and lhen cornwed be&vecn patient; with and without toxicity revealed striking diLrences in three of the six varisblcs. the most significant of which was in the diffusing capacity for carbon monoxide (DLCO). In an attempt to assess the diagnostic accoracy of this marked decrease in D,_CO in patients with pulmonary toxicity, we found an optimal sensitivity of 100% and a specificity of 89% associated with a decrease in DLCO of ~15% between soy two successive tests. At the time intervals used in this study, however, serial measurements of D, CO did not demonstrate that a decreax was an early marker of the later development of pulmonary toxicity.
Rather, in patients with respiratory symptoms and new or progressive pulmonary infiltrates, a meaoisgful worsening of D,CO occurred in all patients whose diagnosis was later confirmed by suppurtiog criteria.
On rhr other hand. to depend on a meon;n&d decrease in D,CO alone to make aa UC~UMIC diagnosis ofpulnww~ toxicity has limiralions. We found that, although a 15% decrease in D,CO was demonstrated at any one determination in 30 of 67 patients. 22 of these patients never developed clinically evident pulmonary toxicity ITable 3). Fourteen of these 22 patients had a subsequent improvement in D,,CO to baseline value, and the other g patients remained clinically asymptomatic with a decreased but stable DLCO at the time of their last follow-up (mean 8 months later that in three c&r of amiodarone pneumonilis pulmonary gallium-67 uptake occurred in all. Although the gallium-67 scan is not diagnostic for a particular pulmonary disorder. there is evidence that it is sensitive to and specific for the alveolitis of pulmonary interstitial disease (IS). The test is widely available and noninvasive and we found it extremely useful in differentiating. with high sensitivity and specificity, heart failure from pulmonary involvement due to amiodarooe. Prospective clinical studies correlating the gallium-67 scan with develoomcnt of pulmonary toxicity may further confirm the diagnostic value of this test. X-my findings. By study destgn, the diagnosis of pulm+ nary toxicity was based in part on chest roentgeoographic findings. Thus, we are unable to state the value of serially performed chest rwntgeoograms as ao early indicator of pulmonary toxicity. It is possible that serial chest roentgeoograms might have provided important information and that early preclinical changes may predate changes in the DLCO.
However, the chest roen,genogiam has been shown to be neither a sensitive nor a specific monitor of the alvealitis of interstitial lung disease (IS).
Present protcwl for diagnostic Ming and criteria. As a result of the present study, we continue to perform and strongly recommend complete pulmonary function testing, including a diffusing capacity for carbon monoxide (DLCO) before initiation of amiodarone therapy and whenever pulmonary toxicity is suspected. It was disappointing that changes in serial pulmonary function did not presage the development ofpulmonary toxicity; for that reason, with the exception of the D,CO. we no longer perform these studies during routine follow-up evaluation. However, some assesstreatment may reduce :be incidence of pulmonary tow~ty. A\ a result of this study we have modified our dosmg schedule. A loading dose of t.lXl mglday for 2 weeks is Followed by a stepwise decrease in dose in an attempt to reach a maintenance dose of 2M) to 400 mg at the end of the 3rd month of treatment. Whether this procedure will Gsoif~amly decrease the incidence of pulmonary toxicity at our ment of vulmonary status during the course of follow-uo ~eern~ prudent. A practical approach would be to obram twb or three measuremettts of D, CO durinn the first few monrhs of therapy in order to evzdua~e the vari&m in the individual patient. After a stable maintenance dose is reached, no further evaluation need be done until pulmonary symptoms develop. At that time. however, ?. 0,CS can be interpreted with increased confidence based on the known variation of the test results in that patient.
The present srudy suyyrsts rim rhr 0, CO andpaliim-67 scanning have dicrp& whe. As a &dt, we have expanded our diagnostic criteria to include a meaningful reduction in diffusingcapacity and a positive gallium-67 scar: in the presace of pulmonary symptoms and new or progressive pulmonary ittliltrates on chest roeotgenogram. Three proposed major criteria and five supporting criteria are summarized in Table 4 . It is suggested that all three of the major criteria be satisfied and that two or more of the suooortine " was to attempt to identify any baseline &ical or laborator; criteria be present to eonfirm the diagnosis. (5) not only stated that initial abnormalities on cheTt roentgenogram or ddfusing capacity were predictive of risk of pulmonary toxicity bu' also recommended that patents with these zbbnormalines be considered lor alternative therapy. Other investigators (IV-21) have endorsed this point of view, but our data do not support :heir recommendation. We found no evidence th*t preexisting lung disease or baseline chest roentgenogram or D,CO abnormalities. either alone or in combmation. were oredicttve of risk of develaoine oulmonarv toxicilv. Al-;hougb our laboratory definition 'of an adnormal &CO IeM)% of oredieted) differed from that of Kudencbuk et al. (<SO% of'predicted) . our results when analyzed slmdarly remain unehaneed. Our fmdinr was consictent with that of included age, his!ory of congestive heart failure or cig&tt, smoking, left ventricular ejection Fraction. total loading dose in grams, loading dose in mglkg per day and duration of loading. Higher maintenance doses did appear to be related to the development of pulmonary toxicity. This is the first demonstration of a relation previously suggested by other investigators (IO,1618). The significant difference in cumolative dose at the 6 month time interval between patents with and witbout pulmonary toxicity was more likely a reflection of the higher maintenance doses taken by panems who later developed pulmonary toxicity than an independent factor predisposing a patient to risk, because the range of cumulative dose at the time of diaenosis WBF so wide 130.4 to since the complktion dfthis formal stud;. Of the 62 patie& in this group who had baseline D,CO measurementr. 35 of whom had preexisting abnormalities in D,CO or chest roentgenogram or a history of pulmonary disease. none to date has developed pulmonary toxicity during a follow-up period that now extends to 35 t 19 months. Thus, wlh careful clinical follow-up. there is no reason that amiodarone cannot be siven safely to most patients regardlesr of preenisting pulmonary status.
The importance of the recognition and diagnosis of pulmonary toxicity, however. cannot be overemphaswJ.
especlally in view of the recent approval of smiodarone for life-threateninc ventricular arrhvthmias. On the other hand. 303.6 g). The fact that pulmonary &xicity can occur abruptly to withhold oFwithdraw potent&y lifesavinp therapy from and without warning during the Iwading phase or Iate in the patients frequently resistant to all other available anti-
